Back to the main directory
Press Release
- Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25% by GlobeNewsWire
- CorMedix inc. Announces Customer Implementation by GlobeNewsWire
- Aktietilbagekøb i Djurslands Bank - transaktioner i uge 25 by GlobeNewsWire
- Clearmind Medicine Adds Leading Israeli Clinical Site to Its Ongoing Clinical Trial for Alcohol Use Disorder by GlobeNewsWire
- Ajay Dhankhar joins Smith+Nephew as Chief Corporate Development & Strategy Officer by GlobeNewsWire
- ASML reports transactions under its current share buyback program by GlobeNewsWire
- Muutoksia Kalmarin johtoryhmässä: Kalmar nimittää Hanna Reijosen henkilöstöjohtajaksi by GlobeNewsWire
- Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary by GlobeNewsWire
- MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development by GlobeNewsWire
- Guardforce AI Strengthens Decade-Long Client Relationships by Securing Long-term Contract with Government Savings Bank by GlobeNewsWire
- ORYZON Announces Submission of Phase III Protocol to FDA to Initiate PORTICO-2 Trial of Vafidemstat in Borderline Personality Disorder (BPD) Patients by GlobeNewsWire
- Grace Therapeutics Announces 2025 Fiscal Year-End Results, Provides Business Update by GlobeNewsWire
- Alaunos Therapeutics Announces $2.0 Million Registered Direct Offering by GlobeNewsWire
- Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program by GlobeNewsWire
- Nano Labs Plans to Apply for License for HKD and Offshore RMB Stablecoin Businesses by GlobeNewsWire
- Rezolve Ai to Join Russell 2000® and Russell 3000® Indices Following Breakout Year of Hypergrowth and Strategic Alliances by GlobeNewsWire
- Jupiter Neurosciences Names Golf Legend Annika Sörenstam as First Nugevia™ Brand Ambassador by GlobeNewsWire
- Oportun Issues Letter to Stockholders Detailing CEO Raul Vazquez’s Record of Proven Leadership by GlobeNewsWire
- Candel Therapeutics Appoints Charles Schoch as Chief Financial Officer by GlobeNewsWire
- Emergent BioSolutions Secures $62.4 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Bolster U.S. Biodefense Supply by GlobeNewsWire
- FLEURY MICHON : Déclaration des opérations de rachat d'actions du 16 au 20 juin 2025 by GlobeNewsWire
- Transactions in Connection with Share Buy-back Program by GlobeNewsWire
- BioStem Technologies Completes Enrollment in Clinical Trial Evaluating BioREtain® Amnion Chorion for Treatment of Diabetic Foot Ulcers by GlobeNewsWire
- Transactions in connection with share buy-back program by GlobeNewsWire
- Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP) by GlobeNewsWire